The mechanisms by which Gal3 participates in cardiovascular disease and influences prognosis are still unclear, although it is recognized that Gal3 has adverse effects on cardiac remodeling and myofibroblast activation [145]. This evidence concerns the gene LGALS3 and cardiovascular disorder.